A new oral drug called VDPHL01 developed by Veradermics, an American biopharmaceutical company, achieved remarkable results in a pivotal Phase II/III clinical trial and is considered to be the first new treatment approved in the United States to reverse male pattern baldness in the past 30 years. The trial results showed that this drug not only performed well in improving hair density, but was also comparable to placebo in terms of safety and tolerability, giving the research team and clinicians high hopes for its prospects.
The study, which included 519 men, compared once-daily medication, twice-daily medication, and a placebo in improving hair coverage. The results showed that 79.3% of the subjects who took VDPHL01 once a day were considered to have improved hair as assessed by themselves and the researchers; among the subjects who took VDPHL01 twice a day, this proportion further increased to 86%. In comparison, only 35.6% of subjects in the placebo group were assessed as having improved hair condition, highlighting the drug's clear clinical advantage.
In terms of objective measures of hair growth, the trial also gave specific data: after six months of treatment, subjects who took the drug twice a day had an average increase in hair density of 33 hairs/cm2 from baseline, while the placebo group only increased by 7.3 hairs/cm2. This result suggests that VDPHL01 not only makes patients subjectively feel "more hair", but also shows a significant increase in the amount of new hair in objective counts.
In terms of safety, the researchers pointed out that during the entire six-month observation period, VDPHL01 was generally well tolerated, its discontinuation rate was similar to that of the placebo group, and no significant increase in serious adverse reactions was observed. This is considered particularly critical because traditional treatments such as androgen receptor inhibition are often limited by sex hormone-related side effects, and safer non-hormonal oral options will be more easily accepted by doctors and patients.
If ultimately approved by the U.S. Food and Drug Administration (FDA), VDPHL01 is expected to be the first non-hormonal oral drug for the treatment of pattern alopecia and the first extended-release formulation based on oral minoxidil designed specifically for the treatment of hair loss to achieve positive results in a Phase III trial. It is currently estimated that approximately 80 million adults in the United States alone suffer from some degree of hair loss, and new treatment options have the potential to significantly change the medication landscape for this large population.
Dr. Maryanne Makredes Senna, assistant professor of dermatology at Harvard Medical School and a member of Veradermics' scientific advisory board, said that based on the results of Study 302, if approved, VDPHL01 has the potential to "change the overall perception of doctors and patients about the treatment of male pattern baldness." She pointed out that an oral therapy that has shown visible improvement in the eyes of nearly 80% of patients and researchers, was generally well tolerated in trials, and belongs to a class of drugs that dermatologists are already familiar with is expected to reshape the existing treatment landscape.
Dr. Michael Gold, another trial investigator, emphasized that VDPHL01 is the first oral extended-release formulation of minoxidil developed specifically for pattern alopecia, and the first such drug to achieve positive results on both efficacy and safety in Phase III clinical studies. According to the company, this delayed-release delivery design aims to minimize the risk of adverse effects on the cardiovascular system while ensuring the stimulating effect of minoxidil, and widen the "window" between the drug's efficacy and safety.
Currently, the follow-up clinical development around VDPHL01 is still progressing, and the industry and regulatory authorities are paying close attention to its other phase III study in male subjects - "Study 304", which is expected to publish results in the second half of 2026. In addition, the company has also initiated a Phase II/III specialized trial "Study 306" for female pattern hair loss to evaluate the efficacy and safety of the drug in the female population, in an effort to expand the indications to a wider group of hair loss patients.
From a drug mechanism perspective, VDPHL01 is essentially an oral extended-release minoxidil tablet, and minoxidil itself has been widely used and proven to promote hair growth. By prolonging the release time of the drug and optimizing the systemic exposure level, the R&D team hopes to minimize the potential cardiovascular risks of traditional oral minoxidil while ensuring sufficient hair follicle stimulation, thereby achieving a more stable balance between safety and efficacy.
Veradermics said in a statement that VDPHL01 uses a proprietary oral extended-release formulation with the goal of "maximizing the effectiveness of minoxidil on hair regrowth while minimizing its impact on cardiac activity." As positive results from key trials continue to be announced, the company is also widely expected to submit a new drug application to the FDA in the next few years, pushing this potential "first" oral non-hormonal hair loss drug towards actual clinical application.